Form 8-K - Current report:
SEC Accession No. 0001104659-24-030552
Filing Date
2024-03-04
Accepted
2024-03-04 17:25:30
Documents
14
Period of Report
2024-03-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm247932d1_8k.htm   iXBRL 8-K 32318
  Complete submission text file 0001104659-24-030552.txt   206850

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA blph-20240301.xsd EX-101.SCH 3024
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE blph-20240301_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE blph-20240301_pre.xml EX-101.PRE 22365
15 EXTRACTED XBRL INSTANCE DOCUMENT tm247932d1_8k_htm.xml XML 3660
Mailing Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Business Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Bellerophon Therapeutics, Inc. (Filer) CIK: 0001600132 (see all company filings)

EIN.: 473116175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36845 | Film No.: 24716088
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)